Atavistik Bio: Valuation, Funding & Investors
Atavistik Bio is a clinical-stage biotechnology company focused on discovering and developing precision allosteric small molecule therapeutics. The company leverages its proprietary AMPS™ platform to advance oral allosteric inhibitors targeting AKT1 for Hereditary Hemorrhagic Telangiectasia (HHT) and JAK2 V617F mutant-selective inhibitors for myeloproliferative neoplasms (MPNs).
Leadership & Board
- Current Number of Employees
- 39
- Current LinkedIn Followers
- 4,948
Latest Estimated Valuation
- Total Amount Raised
- $120M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $120M
- Latest Funding Round
- Series B
Company Momentum
PositiveAtavistik Bio LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Atavistik Bio had 39 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Atavistik Bio had 4,948 followers as of November 9, 2026. The number of followers increased by 21 (0.43%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 18, 2025 | Series B | $120.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Lux Capital | Series B |
| Nextech Invest | Series B |
| The Column Group | Series B |
| Regeneron Ventures | Series B |
Similar Companies
A snapshot of private companies similar to Atavistik Bio, helping you discover and navigate related company profiles.
Related News and Analysis








